ArticleMolecular cancer2024
Deciphering the role of LGALS2: insights into tertiary lymphoid structure-associated dendritic cell activation and immunotherapeutic potential in breast cancer patients.
Article in Molecular cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- The immunology of human breast cancer.Nature reviews. Immunology · 2026Review
- Integrated multi-omics and single-cell analysis of galectins and immune associations in triple-negative breast cancer.Translational oncology · 2026Article
- CMTM3 links inflammation-related transcriptional dysregulation to immune and therapeutic stratification in gastric cancer.Translational oncology · 2026Article
- Crosstalk Between CTSBAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Spatial Immune Coding in Tumor-Draining Lymph Nodes: Functional Compartmentalization of Immune Activation and Immunosuppression.International journal of molecular sciences · 2026Review
- Tertiary lymphoid structures in breast cancer: Mechanistic insights, subtype-specific patterns, and therapeutic implications.World journal of surgical oncology · 2026Review
- The formation and function of tertiary lymphoid structures.Biomarker research · 2026Review
- Tumor immune microenvironment states inferred from TLS-associated immune-cell composition stratify prognosis in hepatocellular carcinoma.Frontiers in immunology · 2026Article
- A Single-Cell Multiomics Pipeline Maps YBX1 as a Functional Biomarker for Immune Evasion and Therapeutic Resistance in Prostate Adenocarcinoma.Human mutation · 2026Article
- Tertiary lymphoid structure can be a potential therapeutic target for head and neck squamous cell carcinoma (Review).Molecular and clinical oncology · 2026Review
- Integrative Multiomics Nominate GGCT as a Crucial Regulator of Immunosuppression in Colorectal Cancer.International journal of genomics · 2026Article
- A multi-dimensional omics framework identifies GPR35 as a driver of M2 macrophage activation and poor prognosis in colorectal cancer.Frontiers in immunology · 2026Article
- Targeting the tripartite axis of immune-metabolic-spatial crosstalk to overcome therapy resistance in breast cancer.Frontiers in immunology · 2026Review
- Multi-omics study of prognostic models and molecular networks related to ovarian cancer.Discover oncology · 2025Article
- PTGER4 Governs Immune Evasion and Therapy Resistance in Kidney Cancer via Ribosome Biogenesis Dysregulation.Journal of cellular and molecular medicine · 2025Article
- ZBP1, an M1 Macrophage-Associated Biomarker Identified by Machine Learning, Suppresses Tumorigenesis and Predicts Immunotherapy Response in Head and Neck Squamous Cell Carcinoma.Journal of cellular and molecular medicine · 2025Article
- Prognostic model for pediatric brain tumors based on tumor microenvironment-specific gene signatures.Discover oncology · 2025Article
- FLT3LG as an inflammatory hub bridging tumor immune surveillance to therapy response in breast cancer.Clinical and experimental medicine · 2025Article
- Role of tertiary lymphoid structures in the tumour microenvironment and immunotherapy response of renal cell carcinoma.Clinical and translational medicine · 2025Review
- Dynamic remodeling of tertiary lymphoid structures in response to cancer therapy: a recent review.Cancer immunology, immunotherapy : CII · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in cancer research have highlighted the pivotal role of tertiary lymphoid structures (TLSs) in modulating immune responses, particularly in breast cancer (BRCA). Here, we performed an integrated analysis of bulk transcriptome data from over 6000 BRCA samples using biological network-based computational strategies and machine learning (ML) methods, and identified LGALS2 as a key marker within TLSs. Single-cell sequencing and spatial transcriptomics uncover the role of LGALS2 in TLS-associated dendritic cells (DCs) stimulation and reveal the complexity of the tumor microenvironment (TME) at both the macro and micro levels. Elevated LGALS2 expression correlates with prolonged survival, which is associated with a robust immune response marked by diverse immune cell infiltration and active anti-tumor pathways leading to a 'hot' tumor microenvironment. The colocalization of LGALS2 with TLS-associated DCs and its role in immune activation in BRCA were confirmed by hematoxylin-eosin (HE), immunohistochemistry (IHC), and in vivo validation analyses. The identification of LGALS2 as a key factor in BRCA not only highlights its therapeutic potential in novel TLS-directed immunotherapy but also opens new avenues in patient stratification and treatment selection, ultimately improving clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.